Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Mirum Pharmaceuticals (MIRM) Gross Margin (2023 - 2025)

Mirum Pharmaceuticals (MIRM) has 3 years of Gross Margin data on record, last reported at 81.02% in Q4 2025.

  • For Q4 2025, Gross Margin changed N/A year-over-year to 81.02%; the TTM value through Dec 2025 reached 51.46%, changed N/A, while the annual FY2025 figure was 80.77%, 501.0% up from the prior year.
  • Gross Margin reached 81.02% in Q4 2025 per MIRM's latest filing, up from 76.98% in the prior quarter.
  • Across five years, Gross Margin topped out at 84.24% in Q1 2023 and bottomed at 74.24% in Q1 2024.
  • Average Gross Margin over 3 years is 79.12%, with a median of 79.0% recorded in 2025.
  • The widest YoY moves for Gross Margin: up -1000bps in 2024, down -1000bps in 2024.
  • A 3-year view of Gross Margin shows it stood at 84.24% in 2023, then fell by -9bps to 76.98% in 2024, then grew by 5bps to 81.02% in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Margin were 81.02% in Q4 2025, 76.98% in Q3 2024, and 74.24% in Q1 2024.